

Ref: FOI/GS/ID 6396

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

10 November 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to intra-vitreous injections or implants.

You asked:

1. Within your trust how many intra-vitreous injections/implants of each of the following drugs have been used in the four-month period from May-August 2020:

- a. Aflibercept*
- b. Bevacizumab*
- c. Brolucizumab*
- d. Dexamethasone*
- e. Fluocinolone*
- f. Ranibizumab*

2. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used from May-August 2020, for each of the following conditions:

Wet Age Related Macular Degeneration (wAMD)

- a. Aflibercept*
- b. Bevacizumab*
- c. Brolucizumab*
- d. Dexamethasone*
- e. Fluocinolone*
- f. Ranibizumab*

Diabetic Macular Oedema (DMO)

- a. Aflibercept*
- b. Bevacizumab*
- c. Dexamethasone*
- d. Fluocinolone*
- e. Ranibizumab*

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- a. *Aflibercept*
- b. *Bevacizumab*
- c. *Dexamethasone*
- d. *Fluocinolone*
- e. *Ranibizumab*

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

- a. *Aflibercept*
- b. *Bevacizumab*
- c. *Dexamethasone*
- d. *Fluocinolone*
- e. *Ranibizumab*

3. Within your trust how many patients have been treated for Uveitis in the four-month period from May to August 2020 with the following?

- a. *Dexamethasone intra-vitreous implants*
- b. *Any other anti-VEGF injections/implants*
- c. *Infliximab*
- d. *Adalimumab*
- e. *Tocilizumab*

Trust response:

- 1.
- a. 1692
- b. 117
- c. NOT USED
- d. 60
- e. 3
- f. 998

2.

Wet Age Related Macular Degeneration (wAMD)

- a. 1159
- b. Do not have data
- c. NOT USED
- d. 1
- e. 0
- f. 634

Diabetic Macular Oedema (DMO)

- a. 338
- b. Do not have data
- c. 20
- d. 0
- e. 189

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- a. 195
- b. Do not have data
- c. 16
- d. 0
- e. 175

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

a. 0

b. Do not have data

c. 0

d. 0

e. 0

3.

a. 23

b. 4

c. 0

d. 0

e. 0